上海透景生命科技股份有限公司 2017 年第三季度报告全文 证券代码：300642 证券简称：透景生命 公告编号：2017-046 上海透景生命科技股份有限公司 所有董事均已出席了审议本次季报的董事会会议。 公司负责人姚见儿、主管会计工作负责人刘娟及会计机构负责人(会计主管 人员)刘娟声明：保证季度报告中财务报表的真实、准确、完整。 2 上海透景生命科技股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 2017 年第三季度报告 2017 年 10 月 1 上海透景生命科技股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 888,152,243.31 | | 340, ...

Financial Performance - The company reported a revenue of RMB 100 million for the first half of 2017, representing a year-on-year increase of 20%[12]. - Total revenue for the reporting period reached CNY 118,947,960.88, an increase of 26.76% compared to CNY 93,834,901.37 in the same period last year[19]. - The company achieved operating revenue of 118.95 million yuan, with reagent revenue accounting for 94.72% at 112.67 million yuan, representing a year-on-year growth of 31.07%[33]. - The company reported a total revenue of RMB 1.5 billion for the first half of 2017, representing a year-on-year growth of 25%[103]. - The company’s operating revenue for the first half of 2017 was CNY 118,947,960.88, representing a 26.9% increase from CNY 93,834,901.37 in the same period of 2016[169]. - The net profit attributable to shareholders was CNY 47,136,717.95, reflecting a growth of 20.26% from CNY 39,197,152.44 year-on-year[19]. - The net profit for the period was 47.14 million RMB, showing a year-on-year increase of 20.26%[53]. - The total profit for the period was CNY 54,404,187.42, which is a 22.4% increase from CNY 44,486,167.91 in the same period last year[169]. - The company reported a basic earnings per share of 0.94 yuan, an increase of 8.05% compared to 0.87 yuan in the same period last year[138]. - The diluted earnings per share also stood at 0.94 yuan, reflecting the same 8.05% increase year-over-year[138]. Research and Development - The company plans to invest RMB 30 million in research and development for new diagnostic products in the upcoming year[12]. - The company invested 12.44 million yuan in R&D, which is 10.46% of its operating revenue during the reporting period[44]. - Research and development expenses totaled 12.44 million RMB, accounting for 10.46% of the company's revenue, with a year-on-year growth of 33.06%[55]. - The company has over 60 ongoing research projects, with 78.33% in the basic research phase and 21.67% in clinical and registration stages[61]. - The company is focusing on the development of high-throughput flow cytometry technology, which is expected to improve testing efficiency by 3-10 times[10]. - The company has focused on developing clinical detection products for cervical cancer screening and personalized medicine, including key gene mutation detection kits[29]. - The company has established multiple advanced technology platforms, including high-throughput flow fluorescence hybridization and chemiluminescence immunoassay platforms[42]. Market Strategy and Expansion - The company has outlined a market expansion strategy targeting Southeast Asia, aiming for a 10% market share within the next two years[12]. - User data showed an increase in the number of active users by 15% compared to the same period last year, reaching 50,000 active users[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share within the next two years[103]. - A strategic acquisition of a local biotech firm was announced, expected to enhance the company's product portfolio and increase market competitiveness[104]. - The company is focusing on expanding its market presence and developing new products to drive future revenue growth[1]. Financial Position and Assets - Total assets increased significantly to CNY 874,405,808.48, a rise of 156.78% from CNY 340,527,968.97 at the end of the previous year[20]. - Net assets attributable to shareholders reached CNY 816,178,143.35, marking an increase of 182.75% from CNY 288,652,497.74 at the end of the previous year[20]. - Current assets totaled CNY 728,408,464.00, significantly up from CNY 211,799,135.41 at the beginning of the period, marking an increase of 244.5%[160]. - Cash and cash equivalents increased to CNY 556,704,196.70 from CNY 116,179,460.74, representing a growth of 378.5%[159]. - The total equity attributable to the parent company at the end of the previous period was 290,170,852.93 CNY[184]. Risks and Challenges - The company faces risks related to regulatory changes in the medical device industry, which may impact future operations[4]. - The company is facing risks related to changes in industry policies, which may impact customer structure, distributor management, and product pricing[91]. - The company faces risks in new product development, as successful R&D must pass through clinical trials and regulatory approvals to obtain medical device registration certificates[94]. - The in vitro diagnostic market is rapidly growing, attracting numerous domestic and international competitors, which increases market competition risks for the company[95]. - The company has developed detailed project plans for fundraising investment projects, but faces risks if market conditions change significantly[95]. Shareholder and Dividend Information - No cash dividends or stock bonuses will be distributed to shareholders for this period[5]. - The company distributed cash dividends of RMB 18 million (including tax) to shareholders based on a total of 60 million shares, at a rate of RMB 3 per 10 shares[100]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[101]. - The company has committed to conducting cash dividends annually for the next three years, with a minimum distribution of 20% of the annual distributable profit[107]. - The total amount for stock repurchase is capped at RMB 10 million, with a condition that the stock price does not exceed the net asset value per share for 20 consecutive trading days[105]. Compliance and Governance - The half-year financial report has not been audited[108]. - The company has not experienced any bankruptcy reorganization matters during the reporting period[109]. - There are no penalties or rectification situations reported during the reporting period[112]. - The company has not faced any media scrutiny during the reporting period[111]. - The commitments made by the company have been fulfilled in a timely manner[107]. Operational Efficiency - The company aims to improve operational efficiency by implementing new technologies, which is projected to reduce costs by 10% over the next year[103]. - The company has established a strict quality management system for its products, adhering to standards such as ISO9001 and ISO13485, to ensure the accuracy of medical diagnostics[92]. - The company has implemented measures to prevent core technology leakage, including signing confidentiality agreements and non-compete contracts with key technical personnel[93].